NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) - Total Liabilities
Based on the latest financial reports, NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) has total liabilities worth $58.36 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore NAMS net assets growth trend to track the company's year-over-year net asset growth rate.
NewAmsterdam Pharma Company N.V. Ordinary Shares - Total Liabilities Trend (2020–2024)
This chart illustrates how NewAmsterdam Pharma Company N.V. Ordinary Shares's total liabilities have evolved over time, based on quarterly financial data. See NewAmsterdam Pharma Company N.V. Ordinar free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
NewAmsterdam Pharma Company N.V. Ordinary Shares Competitors by Total Liabilities
The table below lists competitors of NewAmsterdam Pharma Company N.V. Ordinary Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TOMRA SYSTEMS ADR/1 NK 1
F:TMR0
|
Germany | €1.19 Billion |
|
Standex International Corporation
NYSE:SXI
|
USA | $809.75 Million |
|
Weihai Guangwei Composites Co Ltd
SHE:300699
|
China | CN¥3.29 Billion |
|
Bangkok Expressway and Metro Public Company Limited
BK:BEM
|
Thailand | ฿133.00 Billion |
|
China Communications Construction Company Limited
F:CYY
|
Germany | €1.55 Trillion |
|
Simmons First National Corporation
NASDAQ:SFNC
|
USA | $21.26 Billion |
|
Huaneng Power International Inc
F:HUP1
|
Germany | €407.69 Billion |
|
HEXPOL AB (publ)
ST:HPOL-B
|
Sweden | Skr8.94 Billion |
Liability Composition Analysis (2020–2024)
This chart breaks down NewAmsterdam Pharma Company N.V. Ordinary Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see NewAmsterdam Pharma Company N.V. Ordinar market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.57 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NewAmsterdam Pharma Company N.V. Ordinary Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NewAmsterdam Pharma Company N.V. Ordinary Shares (2020–2024)
The table below shows the annual total liabilities of NewAmsterdam Pharma Company N.V. Ordinary Shares from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $107.12 Million | +82.47% |
| 2023-12-31 | $58.70 Million | +21.21% |
| 2022-12-31 | $48.43 Million | +326.24% |
| 2021-12-31 | $11.36 Million | -8.42% |
| 2020-12-31 | $12.41 Million | -- |
About NewAmsterdam Pharma Company N.V. Ordinary Shares
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. Th… Read more